In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets. We continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030.
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca
We have
183
projects in our pipeline
